http://lifestyle.matomyseo.com/

Author: SOLIGENIX, INC.

Soligenix Details Recent Progress and Upcoming Milestones

February 13, 2026
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet’s Disease Published in Rheumatology (Oxford)

December 20, 2025
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

December 19, 2025
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

November 21, 2025